MIDDLE EAST AND AFRICA GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

MIDDLE EAST AND AFRICA GLUCAGON-LIKE PEPTIDE-1 (GLP-1) AGONISTS MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

During the forecast period, the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is set to witness a CAGR of more than 9% during the forecast period (2022 - 2027). The market is estimated to reach a value of more than USD 160 million by 2027.

The COVID-19 pandemic positively impacted the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market. Diabetes and uncontrolled hyperglycemia are risk factors for poor outcomes in patients with COVID-19 including an increased risk of severe illness or death. People with diabetes have a weaker immune system, the COVID-19 complication aggravates the condition, and the immune system gets weaker very fast. People with diabetes have more chances to get into serious complications rather than normal people.

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are a class of medications used for the treatment of type 2 diabetes and some drugs are also approved for obesity. One of the benefits of this class of drugs over sulfonylureas or meglitinides is that they have a lower risk of causing hypoglycemia. Besides being important glucose-lowering agents, GLP-1RAs have significant anti-inflammatory and pulmonary protective effects and an advantageous impact on gut microbes’ composition. Therefore, GLP-1RAs have been potential candidates for treating patients affected by COVID-19 infection, with or even without type 2 diabetes, as well as excellent antidiabetic (glucose-lowering) agents during COVID-19 pandemic times.

73 million adults (20-79) are living with diabetes in the IDF MENA Region in 2021. This figure is estimated to increase to 95 million by 2030. 48 million adults in the IDF MENA Region are living with Impaired Glucose Tolerance, which places them at increased risk of developing type 2 diabetes. Diabetes is responsible for 796,000 deaths in the IDF MENA Region in 2021. USD 33 billion was spent on healthcare for people with diabetes in 2021.

The Middle East and African region had witnessed an alarming increase in the prevalence of diabetes, in recent years, the rate of diabetes is at an all-time high, mainly due to lifestyle changes. Diabetes is associated with many health complications. Patients with diabetes require many corrections throughout the day to maintain nominal blood glucose levels, such as administering additional insulin or ingesting additional carbohydrates by monitoring their blood glucose levels.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsDulaglutide Segment is expected to dominate the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market

Dulaglutide drug is expected to dominate the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market with a revenue of more than USD 93 million registering a CAGR of more than 12%.

GLP1RAs have been available internationally and are now recommended for use when escalation of treatment for type 2 diabetes is required after metformin and lifestyle management. They can be safely used with all other glucose-lowering therapies except vildagliptin. Dulaglutide (Trulicity) is a weekly subcutaneous GLP1RA that reduces HbA1c with additional weight loss and cardiorenal protection benefits. Therapy with dulaglutide allows many patients to reach and maintain target HbA1c without insulin and/or sulfonylureas, eliminating the associated hypoglycemia risk. GLP1RAs elicit greater weight reduction and are recommended over SLGT2 inhibitors when cerebrovascular disease other than heart failure or renal disease predominates.

The UAE Ministry of Health granted the marketing authorization for Lilly’s Trulicity (dulaglutide) solution for injection, a once-weekly, injectable solution designed to improve glycaemic control in adults with type 2 diabetes. Trulicity (dulaglutide) is also used to reduce the risk of non-fatal stroke in adults with type 2 diabetes mellitus who have multiple cardiovascular risk factors or established cardiovascular disease, as an adjunct to diet, exercise, and standard of care therapy. This decision made Eli Lilly and Company’s Trulicity the first and only GLP1 receptor agonist approved to provide a cardiovascular benefit in people with multiple CV risk factors or with established cardiovascular disease.

Governments in the ME have identified the threat of diabetes and started to respond with various policies, initiatives, and programs. Six out of 15 countries in this region still do not have national operational action policy for diabetes. Many countries still do not have a national strategy to reduce overweight, obesity, and physical inactivity, which are important risk factors for diabetes. Most counties have fully implemented national diabetes treatment guidelines. However, constant measures are being taken to minimize the diabetic complications.

Owing to the rising rate of obesity, growing genetic factors for type-2 diabetes, the increasing prevalence, and the aforementioned factors it is likely that the market will continue to grow.

Saudi Arabia is Expected to Dominate the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market

Saudi Arabia holds the highest market share in the Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market and is also expected to register a CAGR of around 10% in the forecast period.

More than one in ten people in Saudi Arabia are now living with diabetes and the prevalence of the disease will almost double by 2045, according to the report by the International Diabetes Federation (IDF). The IDF report mentioned that 4.27 million people in Saudi Arabia, which has a population of about 34.8 million have diabetes, while a further 1.86 million people have the disease but are yet to be diagnosed. This figure will increase to 5.6 million by 2030 and further to 7.5 million by 2045. Glucagon-like peptide-1 receptor agonists are a class of prescription medications that are effective in the treatment of type 2 diabetes. In addition to lowering blood glucose levels to help treat type 2 diabetes, GLP-1 agonists also resulted in weight loss and other metabolic health benefits. GLP-1 medications are safe, effective, and have relatively few side effects. Any common side effects that patients may experience while taking GLP-1s, such as nausea, are manageable.

There have been constant innovations and studies relating to drug molecules or formulation technologies. For instance, Hanmi Pharmaceutical in September 2021 announced that its new, long-acting diabetes biologic drug, efpeglenatide (GLP-1 RA), was shown to significantly reduce incidences of major adverse cardiovascular events (MACE) and kidney disease in the results of its global, large-scale clinical trial with more than 4,000 patients adding to the efficacy of the drug.

Saudi Government, in July 2022, announced that Saudi Arabia has seen growing demand for quality healthcare services spurred by changes including an increasing and aging population, and a growing prevalence of lifestyle diseases such as diabetes and obesity. The government and private sector are both involved to work on healthcare entities, certifications, and regulations. The government is taking steps to have 100 percent of Saudi citizens covered by insurance and is working towards ensuring affordability, access, and quality digital healthcare and primary care with cost-effectiveness.

Owing to the aforementioned factors the market is expected to grow during the forecast period.

Competitive Landscape

The Middle East and African Glucagon-like Peptide-1 (GLP-1) Agonists Market is consolidated, with four major manufacturers namely Eli Lilly, Sanofi, Novo Nordisk, and AstraZeneca holding their presence in all regions. Currently, no generic versions of the GLP-1s are available in the market since the drugs are patent protected.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.